Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia

Abstract

Background/Objectives.In Colombia, the HPV vaccine was launched in 2012 in the context of a school-based national vaccination program targeting girls aged 9-14 and offering catch up vaccination for girls aged 14-17. In this study, we evaluated the program's impact on type-specific HPV infection by comparing HPV cervical prevalence among vaccinated and non-vaccinated women.Methods. This is a comparative cross-sectional study conducted 5 years after the quadrivalent HPV vaccination implementation in a sentinel Colombian City. This study included young women (18-25 years old) who had been vaccinated in the catch-up group and were attending universities and technical institutions, and women who attended primary health care facilities for Pap-smear screening. The HPV prevalence of 1287 unvaccinated women was compared with the prevalence of 1986 vaccinated women.Results. The prevalence of HPV 16/18 infections was significantly lower in vaccinated compared to unvaccinated women (6.5% Vs 15.4%; p<0.001), whereas for HPV 6 /11 infections, a decrease of 63.7% in vaccinated women (1.02% Vs 2.81%) was observed. The adjusted effectiveness to HPV16/18 was 61.4%, 95% CI: 54.3-67.6%. However, the effectiveness against HPV16/18 was significantly higher among women vaccinated before Cancer Research.

High-risk HPV prevalence and vaccination coverage among Indigenous women in the Colombian Amazon: Implications for cervical cancer prevention. Cross-sectional study

“…In the communities of the Paujil Reserve, genotype 16 was the number one genotype, followed by 52 , 66 and 68 , all in second place. Angarita & Forero [ 9 ] found genotype 16 to be the number one followed by genotypes 31 and 39 ; Cómbita et al [ 26 ] also described genotype 16 as number one, followed by 52 , 58 and 51 in an unvaccinated population of the city of Bogota. Puerto et al [ 10 ] reported genotype 16 as number one, followed by 52 and 51 .…”

“…HPV-DNA was screened for 19 HR and 9 LR genotypes through the use of the Anyplex II 1 Real Time Polymerase Chain Reaction (TR-PCR) HPV 28 by SEEGENE 1 detection technique. The high oncogenic risk viral genotypes (HR-HPV) were: 16,18,26,31,33,35,39,45,51,52,53,56,58,59,66,68,69,73,82. The LR-HPV genotypes were : 6, 11, 40, 42, 43, 44, 54, 61 and 70.…”

Prevalence of high‐risk HPV among marginalized urban women in India and its implications on vaccination: A cross sectional study

“…21 They also emphasize that the monitoring of HPV vaccines post licensure plays an important role in assessing the progress of immunization programs, demonstrating the impact of vaccines on the population, and providing data for policy needs. 22,23 A study in northern Zimbabwe suggested that determining whether cross-immunization against genotypes causing invasive cervical cancer develops after administration of the vaccines in current use is very important. 24 A limitation of the study is that as the proportion of women who came forward for screening was less than half, prevalence has been calculated based on women who were screened.…”

“…Studies in Columbia and Brazil show that HPV types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the protective effects of current vaccines are assessed 21 . They also emphasize that the monitoring of HPV vaccines post licensure plays an important role in assessing the progress of immunization programs, demonstrating the impact of vaccines on the population, and providing data for policy needs 22,23 . A study in northern Zimbabwe suggested that determining whether cross‐immunization against genotypes causing invasive cervical cancer develops after administration of the vaccines in current use is very important 24 …”